Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E

Biochemistry

Volumn 49, Issue 11, 2010, Pages 2510-2519

  Kukreja, Roshan V ^a   Sharma, Shashi K ^b   Singh, Bal Ram ^a  

^a UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION MECHANISMS; BOTULINUM NEUROTOXINS; CLINICAL SYNDROMES; CLOSTRIDIUM BOTULINUM; DISULFIDE BONDS; FLACCID MUSCLE PARALYSIS; FLEXIBLE CONFORMATION; HYDROPHOBIC SEGMENT; INTRACELLULAR SUBSTRATE; MECHANISTICS; MOLECULAR BASIS; NEUROMUSCULAR JUNCTIONS; PHYSIOLOGICAL TEMPERATURE; POLYPEPTIDE CHAIN; SEROTYPES; SINGLE CHAINS; SUBSEQUENT REDUCTION;

CLOSTRIDIUM; ENZYME ACTIVITY;

TOXIC MATERIALS;

BOTULINUM TOXIN E; PROTEINASE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ARTICLE; BASAL BODY TEMPERATURE; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; DISULFIDE BOND; HYDROPHOBICITY; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; CIRCULAR DICHROISM; CLOSTRIDIUM BOTULINUM; DISULFIDES; ENDOPEPTIDASES; ENZYME ACTIVATION; MODELS, MOLECULAR; OXIDATION-REDUCTION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TEMPERAMENT;

CLOSTRIDIUM BOTULINUM;

EID: 77949501119     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi902096r     Document Type: Article

References (46)

1. Singh, B. R. (2006) Botulinum neurotoxin structure, engineering, and novel cellular tafficking and targeting. Neurotoxicity Res. 9, 73-92.
2. Caya, J. G., Agni, R., and Miller, J. E. (2004) Clostridium, botulinum and the clinical laboratorian. Arch. Pathol. Lab. Med. 128, 653-662.
3. Cai, S., and Singh, B. R. (2007) Botulism diagnostics: from clinical symptoms to in vitro assays. Crit. Rev. Microbiol. 33, 109-125.
4. Klein, A. W. (2004) Therapeutic potential of botulinum toxin. Dermayol. Surg. 30, 452-455.
5. Bigalke, H., and Rummel, A. (2005) Medical aspects of toxin weapons. Toxicology 214, 210-220.
6. Dastoor, S. F., Misch, C. E., and Wang, H. L. (2007) Botulinum toxin (Botox) to enhance facial macroesthetics: a literature review. J. Oral Implantol. 33, 164-171.
7. Aoki, K. R., and Guyer, B. (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 8, 21-29.
8. Singh, B. R. (2002) in Scientific and Therapeutic Aspects of Botulinum Toxin (Brin, M. F., Jankovic, J., and Hallet, M., Eds.) pp 75-88, Lipincott Williams and Wilkins, Philadelphia, PA.
9. Menestrina, G., Schiavo, G., and Montecucco, M. (1994) Molecular mechanisms of action of bacterial protein toxins. Mol. Aspects med. 15, 79-193.
10. Poulain, B., Popoff, M., and Molgó, J. (2008) How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J. 1, 14-87.
11. Schiavo, G., Matteoli, M., and Montecucco, C. (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev. 80, 111-155.
12. Singh, B. R., and DasGupta, B. R. (1990) Conformational changes associated with the nicking and activation of botulinum neurotoxin type E. Biophys. Chem. 38, 123-130.
13. DasGupta, B. R., and Sugiyama, S. (1977) in Perspectives in Toxinology (Bernheimer, A. W., Ed.) pp 87-119, John Wiley and Sons, New York.
14. Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R., and Stevens, R. C. (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5, 898-902.
15. Puffer, E. B., Lomneth, R. B., Sarkar, H. K., and Singh, B. R. (2001) Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process. Biochemistry 40, 9374-9378.
16. Kumaran, D., Eswaramoorthy, S., Furey, W., Navaza, J., Sax, M., and Swaminathan, S. (2009) Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 386, 233-245.
17. Cai, S., and Singh, B. R. (2001) Role of the disulfide cleavage induced molten globule state of type A botulinum neurotoxin in its endopeptidase activity. Biochemistry 40, 15327-15333.
18. Gimenez, J. A., and Sugiyama, H. (1987) Simplified purification method for Clostridium botulinum type E toxin. Appl. Environ. Microbiol. 53, 2827-2830.
19. Singh, B. R., Foley, J., and Lafontaine, C. (1995) Physicochemical and immunological characterization of type E botulinum neurotoxin binding protein purified from Clostridium botulinum. J. Protein Chem. 14, 7-18.
20. Singh, B. R., and DasGupta, B. R. (1989) Structure of heavy and light chain subunits of type A botulinum neurotoxin analyzed by circular dichroism and fluorescence measurements. Mol. Cell. Biochem. 86, 87-95.
21. Cai, S., Sarkar, H. K., and Singh, B. R. (1999) Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 38, 6903-6910.
22. Ragone, R., Colonna, G., Balestrieri, C., Servillo, L., and Irace, G. (1984) Determination of tyrosine exposure in proteins by secondderivative spectroscopy. Biochemistry 23, 1871-1875.
23. Li, L., and Singh, B. R. (1999) High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain. Protein Exuression Purif. 17, 339-344.
24. Schiavo, G., Rossetto, O., Santucci, A., DasGupta, B. R., and Montecucco, C. (1992) Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 267, 23479-23483.
25. Blasi, J., Chapman, E. R., Link, E., Binz, T., Yamasaki, S., De camilli, P., Südhof, T. C., Niemann, H., and Jahn, R. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365, 160-163.
26. Humeau, Y., Doussau, F., Grant, N. J., and Poulain, B. (2000) How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82, 427-446.
27. Simpson, L. L., Maksymowych, A. B., Park, J. B., and Bora, R. S. (2004) The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J. Pharmacol. Exp. Ther. 308, 857-864.
28. Fischer, A., and Montal, M. (2007) Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem. 282, 29604-29611.
29. Breidenbach, M. A., and Brunger, A. T. (2005) New insights into clostridial neurotoxin-SNARE interactions. Trends Mol. Med. 11, 377-381.
30. Woody, R. W. (1995) Circular dichroism. Methods Enzymol. 246, 34-71.
31. Sharma, S., and Singh, B. R. (2004) Enhancement of the endopeptidase activity of purified neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 43, 4791-4798.
32. Kukreja, R., and Singh, B. R. (2009) in Microbial Toxins: Current Research and Future Trends (Proft, T., Ed.) pp 15-40, Caister Academic Press, New York.
33. Montecucco, C., and Schiavo, G. (1995) Structure and function of tetanus and botulinum neurotoxins. O. Rev. Bioophys. 28, 423-472.
34. Breidenbach, M. A., and Brunger, A. T. (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925-929.
35. Brunger, A. T., Breidenbach, M. A., Jin, R., Fisher, A., Santos, J. S., and Montai, M. (2007) Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 3, 1191-1194.
36. Chen, S., Hall, C., and Barbieri, J. T. (2008) Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J. Biol. Chem. 283, 21153-21159.
37. Kumaran, D., Rawat, R., Ahmed, S. A., and Swaminathan, S. (2008) Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog. 4, e1000165.
38. Cai, S., Singh, B. R., and Sharma, S. (2007) Botulism diagnostics: from clinical symptoms to in vitro assays. Crit. Rev. Microbiol. 33, 109-125.
39. Sharma, S., Cai, S., and Singh, B. R. (2008) Here a method, there a method, everywhere many methods. What should a laboratory do to validate an assay for the detection of botulinum neurotoxins? Botulinum J. 1, 183-198.
40. Fields, P. A. (2001) Protein function at thermal extremes: balancing stability and flexibility. Comn. Biochem. Physiol. 129, 417-431.
41. Betz, S. F. (1993) Disulfide bonds and the stability of globular proteins. Protein Sci. 10, 1551-1558.
42. Cai, S., and Singh, B. R. (2001) A. correlation between differential structural features and the degree of endopeptidase activity of type A botulinum neurotoxin in aqueous solution. Biochemistry 40, 4693-4702.
43. Swaminathan, S., and Eswaramoorthy, S. (2000) Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7, 693-699.
44. Schiavo, G., Benfenati, F., Poulain, B., Rossetto, O., Polverino de Laureto, P., DasGupta, B. R., and Montecucco, C. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by a proteolytic cleavage of synaptobrevin. Nature 359, 832-835.
45. Eubanks, L.M., Hixon, M.S., Jin, W., Hong, S., Clancy, CM., Tepp, W. H., Baldwin, M. R., Malizio, C. J., Goodnough, M. C., Barbieri, J. T., Johnson, E. A., Boger, D. L., Dickerson, T. J., and Janda, K. D. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.Proc. Natl. Acad. Sci. U.S.A 104, 2602-2607.
46. Silvaggi, N. R., Boldt, G. E., Hixon, M. S., Kennedy, J. P., Tzipori, S., Janda, K. D., and Allen, K. N. (2007) Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem. Biol. 14, 533-542.